CSI’s Strategic Approach to Mitigating Clinical Trial Supply Disruption Recent developments in U.S. trade policy are shaking up supply chains, not just within the United States but worldwide. With the re-introduction of Trump-era tariffs on key goods, companies engaged in clinical research must rethink their sourcing and logistics strategies. Clinical Services International (CSI) is proactively addressing these challenges to support our clients amid this uncertain climate. Wh

We’re proud to share that CSI is now fully registered and qualified with SAM.gov and BARDA , enabling us to support U.S....

A Global Pharmaceutical Sponsor’s Challenge A global pharmaceutical sponsor conducting a Phase III clinical trial needed Semaglutide, a GLP-1 receptor agonist, as a comparator drug. The study spanned multiple regions, including North America, Europe, and Asia-Pacific. This required a consistent and compliant supply of the drug across various regulatory landscapes. The sponsor needed a reliable partner to source Semaglutide efficiently while ensuring batch consistency, Certifi

Which Trends Will Shape Clinical Trial Supplies in 2025? The clinical trial supply industry is rapidly evolving. This change is driven by...

At Clinical Services International (CSI), we continually strive to exceed the expectations of our pharmaceutical and biotech partners by...

CSI is excited to have our Managing Director Vanessa Dekou featured on the front cover of Life Sciences Magazine! This recognition is not only a personal achievement but a testament to the incredible work of the Clinical Services International team. We have been driving excellence in clinical trial services, making a real impact to clinical research and patients lives. Read the Life Sciences Review article here.

Ensuring Efficiency, Compliance and Success Full supply chain management in clinical trial supply encompasses the comprehensive oversight and coordination of all activities involved in the sourcing, packaging, distribution and management of clinical trial comparator drugs and ancillaries. The goal is to ensure that these materials are available at the right place, at the right time, in the right condition, and in the correct quantities, all while complying with regulatory req

The growth in the biosimilar market since 2006 has been significant. Biosimilars have no meaningful clinical differences between the originator medicine in terms of safety and efficacy and are typically less expensive than the originator. These factors lead to the popularity of biosimilars to help bring safe and effective drugs to market at an affordable price What are biosimilars and biological medicines? A biosimilar medicine is a type of biological medicine that is develo

Innovation in oncology drug development is granting cancer patients access to life-changing therapies. The industry continues to conduct...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc

Webinar: How to identify and manage risks in clinical trial supplies and comparator sourcing CSI hosted a webinar with Xtalks on Monday 16 November 2020 on how to identify and manage risks in clinical trial supplies and comparator sourcing. If you joined us on the day, we hope you had a great experience and took away some interesting learnings from our discussion. The webinar, hosted by Vanessa Dekou and Kotaro Yoshizawa, centred on discussing the risks involved in clinical t